Transcatheter Arterial Embolization with N-Butyl-2 Cyanoacrylate Glubran 2 for the Treatment of Acute Renal Hemorrhage Under Coagulopathic Conditions.

BACKGROUND

Transcatheter arterial embolization (TAE) for acute renal hemorrhage (RH) under coagulopathic conditions with N-butyl-2 cyanoacrylate (NBCA) is rarely described in the literature, and a consensus on the efficacy and safety of NBCA under this condition has not been reached. The present study aimed to evaluate the efficacy and safety of TAE using NBCA Glubran 2 in the treatment of acute RH under coagulopathic conditions.

METHODS

Eight patients who underwent TAE with NBCA Glubran 2 for acute RH under coagulopathic conditions were collected.

RESULTS

NBCA Glubran 2 was employed as the sole embolic material in 6 patients. In the remaining 2 patients, NBCA Glubran 2 was employed for secondary embolization. Under coagulopathic conditions, both technical success and clinical success were achieved in treating acute RH with NBCA Glubran 2 in all patients. During a mean follow-up time of 30.1 months, neither persistent nor recurrent active hemorrhage required a repeated endovascular or surgical treatment for hemostasis. No Glubran 2-related complications occurred. In addition, there was no significant difference between the evaluated glomerular filtration rate level before and after one week of Glubran 2 embolization (P = 0.88; CI, -32.4 to 37.4).

CONCLUSIONS

TAE with NBCA Glubran 2 may be a safe alternative treatment for the management of RH under coagulopathic conditions. In particular, this method appears to be a potentially attractive alternative when conventional embolic materials fail in patients with ongoing hemodynamic instability or even under severe coagulopathic conditions.